Back to search
FDAFDA · Food and drugs·Recall number D-0920-2017

Montelukast Sodium Oral Granules, 4 mg pouch, Rx only, Mylan Pharmaceuticals Inc., Morgantown, WV --- NDC 0378-6040-93

Published June 21, 2017 · Recall initiated: May 9, 2017

Summary

FDA records drug Class III recall D-0920-2017, published June 21, 2017 and initiated May 9, 2017. Recalling firm: Mylan Pharmaceuticals Inc.; Status: Terminated; Reported quantity: 11,624 pouches; Lot: Batch 3074707, exp 02/2018. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impurities/Degradation Specifications; out of specification results for Sulphoxide Impurity and Total Impurities

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Mylan Pharmaceuticals Inc.
Distributor
Nationwide
Lot
Batch 3074707, exp 02/2018
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Montelukast Sodium Oral Granules, 4 mg pouch, Rx only, Mylan Pharmaceuticals Inc., Morgantown, WV --- NDC 0378-6040-93 recalled?

Yes. FDA published recall D-0920-2017 on June 21, 2017. Reported hazard: Failed Impurities/Degradation Specifications; out of specification results for Sulphoxide Impurity and Total Impurities

What should I do if I have this product?

Voluntary: Firm initiated · Letter